Quantum BioPharma Advances Clinical Trial for Rare Inflammatory Condition
TL;DR
Quantum BioPharma (NASDAQ: QNTM) received HREC approval in Australia for a Phase 2 trial targeting chronic pain.
FSD202, based on ultra-micronized PEA, aims to reduce pain in patients with MCAS by targeting inflammation-related conditions.
The trial may offer a new therapeutic option for MCAS, a debilitating disorder, emphasizing the need for safe alternatives.
Quantum BioPharma's FSD202 trial aims to advance clinical development in treating chronic pain with innovative biotech solutions.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma has secured human ethics review committee approval in Australia to initiate a Phase 2 clinical trial for FSD202, a potential treatment for chronic widespread musculoskeletal nociplastic pain associated with Mast Cell Activation Syndrome (MCAS).
The randomized, double-blind, placebo-controlled study will enroll 60 patients and evaluate pain reduction over a 56-day period. FSD202, based on ultra-micronized palmitoylethanolamide (PEA), represents a novel therapeutic approach for addressing inflammation-related conditions.
MCAS is a complex and debilitating disorder currently lacking a definitive cure. The trial's significance lies in its potential to provide patients with a safe, targeted treatment option for managing chronic pain associated with this challenging syndrome.
By focusing on PEA, a compound known for its anti-inflammatory properties, Quantum BioPharma aims to address an unmet medical need. The study could represent a critical step toward developing more effective interventions for patients suffering from MCAS-related chronic pain.
The clinical trial underscores the company's commitment to advancing innovative therapies for complex medical conditions, potentially offering hope to patients who have limited treatment options.
Curated from InvestorBrandNetwork (IBN)
